Neothetics initiates body contouring study

Thursday, October 1, 2015

Neothetics, a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, has initiated the safety study, LIPO-202-CL-21, of LIPO-202, the first noninvasive injectable drug candidate for reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects. This is a supplemental safety study that Neothetics expects to submit to the FDA as part of the company’s NDA package for LIPO-202, which the company anticipates filing in the second half of 2016.

[Read More]